Autologous Dermal Papilla Cell Therapy (EPI-001): Landmark Phase 1/2a Clinical Trial Dosing Confirms Micro-Injected Hair Follicle Spheroids Rebuild Miniaturized Root Architecture Without Systemic Drug Toxicity

For more than seventy years, surgical hair restoration has remained a strict zero-sum procedure: surgeons can only extract healthy hair follicles from dense donor zones on the back of the head and relocate them to the hairline or crown. Once a patient’s natural donor bank is depleted, surgical hair transplantation options cease completely, while oral medications only slow ongoing shedding.

What Is It and How Does It Work?

• The Root Cause of Miniaturization: In androgenetic alopecia, hair loss is driven by a steady depletion of dermal papilla cell volume. Under chronic exposure to dihydrotestosterone (DHT) and micro-inflammation, dermal papilla cells undergo apoptosis or migrate out of the bulb. Once the cell count inside the papilla drops below a critical threshold, the follicle can no longer signal epithelial stem cells to build thick hair, causing the root to shrink into a fine, translucent vellus strand.
• The Culture Bottleneck Overcome: Historically, when scientists tried multiplying human dermal papilla cells in flat 2D petri dishes, the cells rapidly lost their genetic identity and stopped expressing trichogenic growth signals within a few cell divisions. Epibiotech overcame this obstacle by culturing primary cells into self-assembling 3D micro-spheroids using customized extracellular matrix scaffolds, preserving high baseline inductive potency.
• Targeted Micro-Injection into the Reticular Dermis: During the in-clinic procedure, millions of cultured, highly inductive autologous dermal papilla spheroids are loaded into a specialized multi-needle micro-delivery device. The cells are injected into the scalp at a uniform depth of 1.5 to 2.5 millimeters, landing directly adjacent to miniaturized hair bulbs.
• Structural Papilla Reconstruction: Once implanted, the donor spheroids integrate into the patient’s existing, miniaturized dermal papillae. This replenishes the missing cell volume, restores canonical Wnt/beta-catenin and alkaline phosphatase (ALP) signaling, and instructs resident hair follicle stem cells to construct a deep dermal hair bulb capable of producing a wide, terminal hair fiber.

The Science: Clear Results from Preclinical Validation and the NCT07618195 Clinical Program

• Preservation of Key Trichogenic Markers: Gene expression assays confirmed that 3D-aggregated EPI-001 cells maintain strong expression of essential hair-inductive genes—including Versican (VCAN), Alkaline Phosphatase (ALP), and LEF1—outperforming standard monolayer cell cultures by more than 5-fold.
• Follicular Terminalization in Xenograft Models: In preclinical immunocompromised models bearing humanized scalp tissue, localized injection of 3D dermal papilla spheroids induced significant hair follicle maturation, converting shallow vellus hairs into deep terminal hair follicles with dense melanin pigmentation.
• Multi-Center Human Phase 1/2a Trial Protocol (NCT07618195): The active human clinical trial evaluates 42 adult male and female participants with mild-to-moderate androgenetic alopecia (Hamilton-Norwood Types III to V and Ludwig Types I to II). The study assesses target area hair count (TAHC), hair shaft diameter via computerized phototrichograms, and cellular engraftment safety over a multi-year tracking protocol.
• Complete Absence of Systemic Adverse Events: Because EPI-001 utilizes a patient’s own living cells (autologous transfer), biopsy tracking and clinical blood draws show zero immune rejection, zero risk of foreign protein sensitization, and zero anti-androgenic side effects on sexual function or mood.

“EPI-001 represents a true regenerative cell therapy that directly addresses the core cellular defect of androgenetic alopecia. By expanding autologous dermal papilla cells in 3D culture to retain their inductive capacity and micro-injecting them into the follicular layer, we can reconstruct the signaling command center of miniaturized follicles and stimulate sustained hair regeneration.”

— Clinical Development Consortium, Epibiotech Human Cell Therapy Program.

When Will It Be Available?

• Current Stage: Actively dosing and evaluating patients in the Phase 1/2a clinical trial (NCT07618195).
• Timeline: Primary safety, tolerability, and preliminary 12-month hair density data will read out across 2027, followed by Phase 2b multi-center efficacy expansion studies in 2028, with commercial clinical cell therapy availability in specialized dermatology surgical centers targeted for 2029 to 2030.

How you can benefit from this treatment now

• The Dawn of Cell-Based Follicle Multiplication: This clinical milestone confirms that hair restoration will eventually transition away from surgical donor hair relocation toward laboratory cell multiplication. In the future, a minor biopsy of a few follicles will provide an effectively unlimited supply of multiplied dermal papilla cells to restore full scalp density.
• Preserve Your Native Follicular Architecture Today: Dermal papilla cell therapies require surviving hair follicle structures to integrate and rebuild; they cannot sprout hair from completely smooth, fibrotic scar tissue where follicles vanished decades ago. Maintaining evidence-based medical care while fine, miniaturized hairs remain visible preserves the target niches needed for cell-therapy injections.
• Stimulate Native Dermal Papilla Inductive Signaling: Controlled clinical studies show that mechanical shear stress activates endogenous Wnt and alkaline phosphatase signaling in dermal papilla cells. Performing a daily 4-minute circular manual scalp massage increases local tissue perfusion and supports cellular vitality.
• Maintain Follicular Vascular Perfusion: Transplanted and surviving dermal papilla cells require adequate capillary networks to support the metabolic demands of anagen growth. Combining gentle weekly 0.5 mm shallow scalp micro-stamping with low-level laser therapy (LLLT) maintains dermal vascular compliance.
• Avoid Unverified “Stem Cell” Clinic Injections: Do not pay for unproven “stem cell hair injections” or uncharacterized stromal vascular fraction (SVF) treatments at commercial clinics today. Authentic dermal papilla cloning requires specialized regulatory cleanroom manufacturing and targeted 3D spheroid culture; unregulated clinic offerings carry risks of localized infections and foreign-body reactions without verifiable hair-regeneration efficacy.